Browsing category:

Drug Research & Development API


Eteplirsen CAS 1173755-55-9

The U.S. Food and Drug Administration approved Eteplirsen CAS# 1173755-55-9 (marketed as Exondys 51) injection, the first drug approved to treat patients with Duchenne muscular dystrophy (DMD). Exondys 51 is specifically indicated for patients who have a confirmed mutation of the dystrophin gene amenable to exon 51 skipping, which affects about 13 percent of the[…]

Read More

The Threat of Antibiotic Resistance

Biapenem CAS No: 120410-24-4 Doripenem CAS No: 148016-81-3 Ertapenem CAS No: 153832-46-3 Imipenem CAS No: 74431-23-5 Meropenem CAS No: 96036-03-2 Panipenem CAS No: 87726-17-8 A new publication is out called “May 19, 2016 – Tackling Drug-Resistant Infections Globally: final report and recommendations” and it highlights the antibiotic-resistant infections which are being seen for the 1st[…]

Read More

Alendronate-CAS-66376-36-1-248x300

Osteoporosis, Paget’s Disease and Alendronate As part of the of drug family called bisphosphonates alendronate sodium works by increasing the thickness of bone by slowing down the cells that usually break down bone. This allows the cells that build bone to work more efficiently. Alendronate can help to reduce the incidence of osteoporosis-related fractures by[…]

Read More

Acamprosate

The drug Acamprosate, sold as Campral®, is used (in combination with counseling) to help people recovering from alcoholism to avoid drinking alcohol again. It reduces alcohol consumption in animal models of alcohol addiction. When a person has been drinking large amounts of alcohol for a long time, it changes the way their brain works. The[…]

Read More

Raltegravir potassium 871038-72-1

Raltegravir potassium is a human immunodeficiency virus integrase strand transfer inhibitor. The drug is soluble in water and slightly soluble in ethanol and methanol as well. The pharmaceutically acceptable salt has been approved for the treatment of HIV-1. The multinational pharmaceutical, Merck has signed an agreement with MPP (Medicines Patent Pool) to license its intellectual property[…]

Read More

The Hyderabad-based pharmaceutical company, Lee Pharma, has recently released a statement which says that Saxagliptin hydrochloride is the most effective substitute for insulin injectables for the treatment of Type-2 diabetes. The statement was made while Lee Pharma said that the multinational company AstraZeneca, which it applied to for the patented diabetes medication Saxagliptin hydrochloride, was[…]

Read More

A new study reveals that patients diagnosed with Type2-diabetes are at an increased risk of developing macrovascular and microvascular complications. Researchers are currently using a drug called Linagliptin which is an anti-diabetic drug that works by increasing the levels of incretins to help control blood sugar levels, especially after meals. According to reports, the cardiovascular[…]

Read More

Recent news from a professional soccer team in Bolivia has surprised the pharmaceutical community. Spain’s El Mundo reported in March of 2015 that the River Plate soccer team, hailing from Argentina, touted the use of Sildenafil to combat altitude sickness. Sildenafil Citrate, the erectile dysfunction therapy known also as Viagra, is certainly a unique remedy[…]

Read More

Carfilzomib shined in pharmaceutical headlines recently with encouraging study data being shared in June 2015. Known as the brand name anticancer therapy Kyprolis, which is marketed by Onyx, the Carfilzomib injection proved to be superior to a Bortezomib-Dexamethasone combination treatment in patients with refractory multiple myeloma. Carfilzomib is an effectual single-agent therapy and proteasome inhibitor[…]

Read More